BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23763320)

  • 1. [Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
    Mráz M; Doubek M; Mayer J
    Klin Onkol; 2013; 26(3):179-85. PubMed ID: 23763320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
    Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
    Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
    Spaargaren M; de Rooij MF; Kater AP; Eldering E
    Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell receptor inhibitors in chronic lymphocytic leukemia.
    Flinn IW
    Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
    Wiestner A
    Blood; 2012 Dec; 120(24):4684-91. PubMed ID: 22875912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
    Davids MS; Brown JR
    Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
    Seda V; Mraz M
    Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards targeted therapy of chronic lymphocytic leukemia.
    Niemann CU; Jones J; Wiestner A
    Adv Exp Med Biol; 2013; 792():259-91. PubMed ID: 24014301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
    Feng G; Wang X
    Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Brown JR
    Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
    Hill RJ; Lou Y; Tan SL
    Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
    Burger JA
    Curr Hematol Malig Rep; 2012 Mar; 7(1):26-33. PubMed ID: 22105489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
    Foluso O; Glick A; Stender M; Jaiyesimi I
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):63-9. PubMed ID: 26775273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeted treatment of chronic lymphocytic leukaemia].
    Niemann CU
    Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.